Ozempic Face: Causes of Facial Volume Loss and How to Address It

"Ozempic face" is a colloquial term describing the gaunt, hollowed facial appearance that some patients develop after significant weight loss on semaglutide.

It is not a recognised medical diagnosis or a listed side effect in the SmPC.

The phenomenon occurs because the face loses subcutaneous fat disproportionately relative to its surface area.

Facial fat pads, particularly the malar (cheek), buccal, and periorbital fat compartments, shrink during caloric deficit. Unlike abdominal or visceral fat, facial fat loss is immediately visible.

Key clinical points:

• Facial volume loss occurs with any method of significant weight loss, not exclusively with semaglutide
• The term emerged in popular media around 2022 and 2023 as Ozempic prescriptions increased sharply
• Patients who lose more than 10% of their body weight are more likely to notice facial changes
• The effect is more pronounced in patients over 40, where age-related collagen loss compounds the appearance of volume depletion
• Ozempic does not cause specific facial tissue damage. The drug has no direct dermatological mechanism of action

Understanding that this is a weight-loss effect, not a drug-specific toxicity, is important for patient counselling.

It occurs equally in patients who lose equivalent weight through dietary restriction or bariatric surgery.

Facial anatomy relies on fat compartments to maintain contour and youthful appearance. These compartments sit in defined layers: deep (sub-SMAS) and superficial (subcutaneous).

During weight loss, both layers deflate.

Structural changes during weight loss:

• Malar fat pad reduction: the cheek fullness diminishes, creating a flattened or sunken midface
• Temporal wasting: fat loss in the temples produces a hollowed, skeletonised appearance
• Periorbital hollowing: under-eye fat loss deepens the tear trough, making patients look tired
• Nasolabial fold deepening: as cheek volume decreases, the fold between nose and mouth becomes more prominent
• Jowl formation: loss of structural fat support allows gravitational descent of lower facial skin

Contributing factors beyond fat loss:

• Collagen degradation: caloric restriction reduces collagen synthesis. Patients in significant caloric deficit produce less type I and type III collagen, accelerating skin laxity
• Elastin changes: skin elasticity diminishes with age. Rapid deflation of facial volume exceeds the skin's capacity to retract, particularly in patients over 45
• Muscle wasting: inadequate protein intake during weight loss leads to loss of facial skeletal muscle, compounding the hollowed appearance

The rate of weight loss is critical. Losing more than 1 kg per week increases the likelihood of noticeable facial changes compared to slower, steadier weight reduction.

Certain patient groups are more susceptible to visible facial volume loss during semaglutide treatment. Identifying these patients early allows proactive counselling.

Higher risk factors:

• Age over 40: natural age-related fat pad atrophy and collagen loss amplify the effect of weight-loss-related volume depletion
• Higher starting weight with rapid loss: patients losing more than 10% of body weight within 6 months are at greatest risk of noticeable facial changes
• Low baseline facial fat: patients with naturally lean faces or angular bone structure have less facial fat reserve. Even modest weight loss produces visible hollowing
• Smoking history: smoking accelerates dermal collagen breakdown by generating reactive oxygen species and reducing dermal blood flow. Former and current smokers develop more pronounced skin laxity
• Low protein intake: patients who do not maintain adequate protein during weight loss lose proportionally more lean tissue, including facial muscle
• Female sex: women typically carry more subcutaneous facial fat than men, so the relative change is often more visible

Lower risk factors:

• Younger patients (under 35) with good skin elasticity often see facial contours restore partially over 6 to 12 months after weight stabilisation
• Patients who lose weight slowly (0.5 kg per week or less) at the 0.5 mg dose give skin more time to adapt
• Patients with naturally round or full facial structures have greater fat reserves and tolerate moderate loss without dramatic visual change

While facial fat loss during weight reduction cannot be entirely prevented, several evidence-based strategies reduce its severity.

Protein intake:

Maintain at least 1.2 to 1.5 g of protein per kg of body weight daily. Protein preserves lean muscle mass throughout the body, including the face.

Patients on semaglutide often eat less overall, making it essential to prioritise protein at each meal.

Rate of weight loss:

Discuss realistic weight loss targets with your prescriber. Losing 0.5 to 1 kg per week is associated with better skin adaptation than losing 1.5 kg or more per week. Remaining at the 0.

5 mg Ozempic dose rather than escalating to 1 mg may be appropriate for patients who prioritise gradual loss.

Micronutrient support:

• Vitamin C: essential cofactor for collagen synthesis. Aim for at least 75 to 90 mg daily through diet (citrus fruits, peppers, broccoli)
• Zinc: supports skin repair and collagen cross-linking. Found in meat, shellfish, and legumes
• Omega-3 fatty acids: support dermal barrier function and reduce inflammatory skin ageing

Hydration:

Dehydrated skin loses elasticity and appears more lax. Maintain at least 1.5 to 2 litres of water daily. GI side effects of Ozempic (nausea, vomiting) increase the risk of dehydration.

Sun protection:

UV exposure accelerates collagen breakdown. Daily broad-spectrum SPF 30 or higher is essential during weight loss to protect remaining collagen.

This is the single most impactful dermatological intervention for maintaining skin quality.

Patients who have already developed noticeable facial hollowing have several treatment options, ranging from non-invasive to surgical.

These should be discussed with a qualified dermatologist or plastic surgeon.

Dermal fillers (hyaluronic acid):

• The most common approach for restoring facial volume. Products such as Juvederm Voluma and Restylane Lyft are designed for deep tissue volumisation
• Typically injected into the cheeks, temples, and tear troughs
• Results last 12 to 18 months before repeat treatment is needed
• Performed as an outpatient procedure. Mild bruising and swelling resolve within 5 to 7 days

Biostimulatory injectables:

• Sculptra (poly-L-lactic acid) stimulates collagen production over 2 to 3 months. Results are more gradual but can last up to 2 years
• Radiesse (calcium hydroxylapatite) provides immediate volume and stimulates collagen
• These are best suited for diffuse volume loss rather than localised hollowing

Skin tightening procedures:

• Radiofrequency microneedling and ultrasound-based devices (e.g. Ultherapy) can improve mild skin laxity
• Results are modest compared to surgical intervention. Multiple sessions are typically required

Surgical options:

• Facelift (rhytidectomy) addresses significant skin laxity and jowling that non-surgical treatments cannot correct
• Fat grafting (autologous fat transfer) uses the patient's own fat to restore facial volume with long-lasting results
• These options are appropriate for patients with severe volume loss who have reached a stable weight

Facial appearance changes can significantly affect quality of life and treatment adherence. Patients should feel comfortable raising these concerns with their prescriber.

Points to discuss at your review appointment:

• Rate of weight loss. If you are losing weight faster than 1 kg per week, your prescriber may recommend staying at 0.5 mg rather than escalating to 1 mg
• Dietary review. A referral to a dietitian can help optimise protein intake and micronutrient balance to support skin health during weight loss
• Psychological impact. Body image concerns are valid and common. If facial changes are causing distress, discuss whether the pace of treatment can be adjusted
• Referral pathways. Your GP can refer to dermatology or plastic surgery for assessment of treatment options if facial volume loss is significant

Important perspective:

Facial volume loss from weight reduction is a cosmetic concern, not a medical emergency.

It should be weighed against the substantial metabolic benefits of weight loss, including improved glycaemic control, reduced cardiovascular risk, and potential remission of type 2 diabetes.

Many patients find that once their weight stabilises, partial facial volume restoration occurs over 6 to 12 months as the body redistributes remaining fat stores.

This natural adaptation is more pronounced in younger patients with good skin elasticity.

Continuing Ozempic or adjusting the dose is a shared decision that should account for the overall risk-benefit balance, not facial appearance alone.